Charles Wiseman, MD, Oncology, Beverly Hills, CA, Cedars-Sinai Medical Center

CharlesLouisWisemanMDFACP, QME

Oncology Beverly Hills, CA

Founder and Director, Briacell Therapeutics Corp

Dr. Wiseman is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Wiseman's full profile

Already have an account?

Education & Training

  • University of Texas MD Anderson Cancer Center
    University of Texas MD Anderson Cancer CenterResidency, Internal Medicine, 1975 - 1976
  • University of Texas MD Anderson Cancer Center
    University of Texas MD Anderson Cancer CenterResidency, Oncology, 1972 - 1973
  • Washington University - Barnes-Jewish Hospital
    Washington University - Barnes-Jewish HospitalResidency, Internal Medicine, 1970 - 1972
  • University of Utah
    University of UtahInternship, Transitional Year, 1969 - 1970
  • David Geffen School of Medicine at UCLA
    David Geffen School of Medicine at UCLAClass of 1969

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2016 - 2018
  • LA State Medical License
    LA State Medical License 1974 - 1975
  • TX State Medical License
    TX State Medical License 1973 - 1980
  • CA State Medical License
    CA State Medical License 1971 - 2022

Awards, Honors, & Recognition

  • Founder and Director BriaCell Therapeutics, 2014-2016

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • BriaCell Announces Grant to Investigator Dr. Saveri Bhattacharya at Sidney Kimmel Cancer Center – Jefferson Health
    BriaCell Announces Grant to Investigator Dr. Saveri Bhattacharya at Sidney Kimmel Cancer Center – Jefferson HealthFebruary 11th, 2020
  • BriaCell to Present Clinical and Scientific Findings with New Insights at Key Oncology Conferences
    BriaCell to Present Clinical and Scientific Findings with New Insights at Key Oncology ConferencesFebruary 19th, 2019
  • BriaCell Announces First Patient Dosed in Phase I/IIa Clinical Study of BriaVax(TM) in Advanced Breast Cancer
    BriaCell Announces First Patient Dosed in Phase I/IIa Clinical Study of BriaVax(TM) in Advanced Breast CancerMay 8th, 2017
  • Join now to see all

Hospital Affiliations